Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 ISIN · KYG1821D1097 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2021-12-09 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships such as Audit, Remuneration, and Nomination and Corporate Governance Committees. It does not contain financial data, earnings, or detailed management discussion. It is an announcement about the board composition and committee roles, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on board information, confirming it is not a full report or other type of filing.
2021-12-09 English
Terms of Reference for the Remuneration Committee
Remuneration Information Classification · 95% confidence The document is titled 'Terms of Reference for the Remuneration Committee of CANbridge Pharmaceuticals Inc.' and details the committee's definitions, constitution, membership, authority, duties, and reporting procedures. It focuses exclusively on the remuneration committee's governance and responsibilities related to executive and director compensation. There are no financial statements, earnings data, or shareholder voting results. The content is a governance-related document specifically about remuneration policies and committee structure, which aligns with the definition of Remuneration Information filings. It is not an announcement or a report publication notice but a substantive governance document on remuneration.
2021-12-09 English
Terms of Reference for the Nomination and Corporate Governance Committee
Governance Information Classification · 95% confidence The document is titled 'Terms of Reference for the Nomination and Corporate Governance Committee' of CANbridge Pharmaceuticals Inc. It details the committee's definitions, constitution, membership, meeting procedures, authority, duties, reporting procedures, and provision of terms of reference. The content focuses on governance practices, board structure, committee responsibilities, and compliance with corporate governance codes. There is no financial data, earnings information, or shareholder voting results. The document is a governance framework outlining internal rules and practices related to board nomination and corporate governance. Therefore, it fits the category of Governance Information (CGR). The document length (12,553 characters) supports it being a full terms of reference document rather than a brief announcement or notice.
2021-12-08 English
Terms of Reference for the Audit Committee
Governance Information Classification · 95% confidence The document is titled 'Terms of Reference for the Audit Committee of CANbridge Pharmaceuticals Inc.' and details the constitution, membership, authority, duties, and procedures of the Audit Committee. It does not contain any financial statements, audit results, or financial performance data. Instead, it outlines governance and procedural rules related to the audit committee's role and responsibilities. This type of document is a governance-related report focusing on internal rules and committee functions rather than an audit report or annual report. Therefore, the most appropriate classification is Governance Information (CGR). The document length (13,333 characters) supports that it is a detailed governance document rather than a brief announcement or certification.
2021-12-08 English
TENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 100% confidence The document is titled 'Tenth Amended and Restated Memorandum and Articles of Association' for Canbridge Pharmaceuticals Inc. It contains detailed legal and structural provisions about the company's memorandum and articles of association, including company objects, share capital, definitions, and governance rules. There is no financial data, earnings information, or management discussion. The document is a legal governance document outlining the company's internal rules and structure. This fits the definition of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not just an announcement or summary.
2021-12-08 English
ANNOUNCEMENT OF ALLOTMENT RESULTS
Regulatory Filings Classification · 95% confidence The document is an official announcement from the Hong Kong Stock Exchange (HKEX) regarding the 'IPO Allotment Results' for CANbridge Pharmaceuticals Inc. It provides links to various files detailing the results of share applications, allotment numbers, and refund instructions. Since this document serves as the official notification and publication of the IPO allotment results, it falls under the category of Regulatory Filings (RNS) as it is a specific regulatory announcement regarding the outcome of a public offering process.
2021-12-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.